• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    1/18/24 12:31:14 PM ET
    $ARAV
    $BFRG
    $CANO
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARAV alert in real time by email

    Gainers

    • Celularity (NASDAQ:CELU) shares moved upwards by 44.7% to $0.27 during Thursday's regular session. The company's market cap stands at $52.8 million.
    • NovoCure (NASDAQ:NVCR) shares increased by 24.15% to $15.42. The market value of their outstanding shares is at $1.6 billion.
    • Jasper Therapeutics (NASDAQ:JSPR) shares moved upwards by 22.18% to $13.0. The market value of their outstanding shares is at $145.0 million.
    • Nuvectis Pharma (NASDAQ:NVCT) shares moved upwards by 14.85% to $8.46. The company's market cap stands at $146.6 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock rose 14.74% to $3.66. The market value of their outstanding shares is at $22.3 million.
    • Venus Concept (NASDAQ:VERO) stock rose 14.28% to $1.32. The company's market cap stands at $7.2 million.

    Losers

    • Aravive (NASDAQ:ARAV) shares decreased by 43.2% to $0.06 during Thursday's regular session. The company's market cap stands at $4.6 million.
    • Processa Pharma (NASDAQ:PCSA) shares decreased by 26.35% to $0.2. The market value of their outstanding shares is at $4.9 million.
    • ZyVersa Therapeutics (NASDAQ:ZVSA) shares fell 22.16% to $0.54.
    • 60 Degrees (NASDAQ:SXTP) shares fell 19.43% to $0.75. The market value of their outstanding shares is at $4.3 million.
    • Cano Health (NYSE:CANO) stock fell 17.58% to $1.97. The market value of their outstanding shares is at $5.6 million.
    • MAIA Biotechnology (AMEX:MAIA) stock fell 17.57% to $1.22. The company's market cap stands at $20.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARAV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAV
    $BFRG
    $CANO
    $CELU

    CompanyDatePrice TargetRatingAnalyst
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    NovoCure Limited
    $NVCR
    7/25/2025$14.50Overweight → Equal Weight
    Wells Fargo
    NovoCure Limited
    $NVCR
    7/8/2025$30.00Buy
    Ladenburg Thalmann
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$4.00Outperform → Market Perform
    BMO Capital Markets
    Jasper Therapeutics Inc.
    $JSPR
    7/8/2025$5.00Outperform → Sector Perform
    RBC Capital Mkts
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Overweight → Neutral
    Cantor Fitzgerald
    Jasper Therapeutics Inc.
    $JSPR
    7/7/2025Outperform → Mkt Perform
    William Blair
    Nuvectis Pharma Inc.
    $NVCT
    4/2/2025$17.00Buy
    Maxim Group
    More analyst ratings

    $ARAV
    $BFRG
    $CANO
    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

    Transaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunityOrganizational realignment reduces operating expenses and sharpens focus on longevity therapeutics FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close n

    3/10/26 8:30:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

    New York, March 05, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks. The full update note is available below. MAIA Biotechnology March 2026 Update Note Highlights from the note include:                                               $30 Million Equit

    3/5/26 4:00:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Former Chief Medical Officer Leupin Nicolas sold $14,636 worth of Ordinary Shares (1,100 units at $13.31), decreasing direct ownership by 1% to 102,979 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    3/5/26 4:33:41 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Former Chief Executive Officer Cordova Ashley covered exercise/tax liability with 17,638 units of Ordinary Shares, decreasing direct ownership by 4% to 422,570 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    3/5/26 4:33:25 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    General Counsel Ben Arye Barak was granted 50,125 units of Ordinary Shares, increasing direct ownership by 26% to 242,453 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    3/5/26 4:32:48 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NovoCure downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded NovoCure from Overweight to Equal Weight and set a new price target of $14.50

    7/25/25 8:59:40 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on NovoCure with a new price target

    Ladenburg Thalmann initiated coverage of NovoCure with a rating of Buy and set a new price target of $30.00

    7/8/25 8:49:22 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Stan bought $9,959 worth of shares (2,700 units at $3.69) and received a gift of 20,000 shares (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    1/12/26 8:44:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $69,999 worth of shares (57,189 units at $1.22) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:18:50 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chaouki Steven M bought $49,999 worth of shares (40,849 units at $1.22), increasing direct ownership by 37% to 151,873 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:16:48 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    SEC Filings

    View All

    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    3/10/26 9:00:41 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Inc. filed SEC Form 8-K: Leadership Update

    8-K - Celularity Inc (0001752828) (Filer)

    3/5/26 5:00:28 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    3/5/26 4:05:37 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Novocure Appoints Company President Frank Leonard as Chief Executive Officer

    Novocure (NASDAQ:NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. "During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their survivals. Frank has been instrumental in creating Novocure's culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to

    12/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    Financials

    Live finance-specific insights

    View All

    Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

    Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch underway Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "In 2025, a record number of patients received treatment with Novocure's Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advanc

    2/26/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

    Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January 14, 2026 Novocure (NASDAQ:NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on the exci

    1/12/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

    67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

    1/8/26 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARAV
    $BFRG
    $CANO
    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

    SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

    11/14/24 3:37:18 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care